Biofourmis Closes $100 Million Series C Funding Round Led by SoftBank Vision Fund 2 to Accelerate U.S. and Global Expansion Funding to advance "home hospital" initiatives with health systems and "beyond the pill" digital therapeutics partnerships with pharmaceutical companies BOSTON, September 3, 2020-- Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2,[1] with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI. In May 2019, Biofourmis closed its $35 million Series B round.